Pfizer and the FDA view Paxlovid as an important complementary tool to vaccination that can help high-risk Americans manage their Covid infections.
The FDA's latest decision means there is now extensive clinical data indicating Paxlovid is safe and effective.
The treatment consists of two medications: nirmatrelvir, which blocks a key enzyme that the Covid virus needs to replicate, and ritonavir, which boosts the first medication's ability to fight the infection.
The story "FDA grants full approval to Pfizer Covid treatment Paxlovid for high-risk adults" has 760 words across 34 sentences, which will take approximately 4 - 7 minutes for the average person to read.
Which news outlet covered this story?
The story "FDA grants full approval to Pfizer Covid treatment Paxlovid for high-risk adults" was covered 3 days ago by CNBC, a news publisher based in United States.
How trustworthy is 'CNBC' news outlet?
CNBC is a fully independent (privately-owned) news outlet established in 2005 that covers mostly economy and business news.
The outlet is headquartered in United States and publishes an average of 0 news stories per day.
It's most recent story was published 1 days ago.
What do people currently think of this news story?
The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
BEAMSTART brings you the latest news, database, and jobs from all around the world on startups, technology, and business. Stay updated with industry news, plug-in to exciting community events, and discover incredible career opportunities with the world's most innovative companies.